CYP19A1 and Cognitive impairment: Five subgroup analyses were performed, namely, gastrointestinal disorders, chemotherapy-induced peripheral neuropathy, aromatase inhibitor-associated arthralgia, aromatase inhibitor-associated joint symptoms, and cognitive impairment.